These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 11217558

  • 21. [Progression of stage I non-seminomatous germ cell tumors during surveillance. Role of positron emission tomography].
    Thuret R, Houlgatte A, Fournier R, Desgrandchamps F, Maszelin P, Gaillard JF.
    Prog Urol; 2000 Dec; 10(6):1224-7. PubMed ID: 11217565
    [Abstract] [Full Text] [Related]

  • 22. The role of 18F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!
    Hung TJ, McLean L, Mitchell C, Pascoe C, Lawrentschuk N, Murphy DG, Iravani A, Singh D, Hofman MS, Zidan L, Akhurst T, Lewin J, Hicks RJ.
    Cancer Imaging; 2019 May 29; 19(1):28. PubMed ID: 31142361
    [Abstract] [Full Text] [Related]

  • 23. False-positive finding in FDG-PET in a patient with seminoma and sarcoidosis.
    Liepe K.
    Acta Clin Belg; 2015 Apr 29; 70(2):138-40. PubMed ID: 25409626
    [Abstract] [Full Text] [Related]

  • 24. Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.
    Joice GA, Rowe SP, Gorin MA, Pierorazio PM.
    Curr Urol Rep; 2018 Nov 09; 19(12):110. PubMed ID: 30413968
    [Abstract] [Full Text] [Related]

  • 25. PET in testicular cancer.
    Becherer A.
    Methods Mol Biol; 2011 Nov 09; 727():225-41. PubMed ID: 21331937
    [Abstract] [Full Text] [Related]

  • 26. [A Case of Metastatic Seminomatous Testicular Tumor with Complicated Diagnosis by FDG-PET].
    Hashizume A, Mizuno N, Kawai M, Kishida T.
    Hinyokika Kiyo; 2016 Jul 09; 62(7):383-7. PubMed ID: 27569358
    [Abstract] [Full Text] [Related]

  • 27. Use of FDG-PET in testicular tumours.
    Huddart RA.
    Clin Oncol (R Coll Radiol); 2003 May 09; 15(3):123-7. PubMed ID: 12801049
    [No Abstract] [Full Text] [Related]

  • 28. Re: 18F-FDG PET/CT Impact on Testicular Tumours Clinical Management.
    Richie JP.
    J Urol; 2015 Oct 09; 194(4):991. PubMed ID: 26382779
    [No Abstract] [Full Text] [Related]

  • 29. [Positron emission tomography in the investigation of malignant testicular tumors].
    Kálvin B, Márián T, Galuska L, Szakáll S, Géczi L, Esik O, Trón L, Bodrogi I.
    Orv Hetil; 2002 May 26; 143(21 Suppl 3):1286-9. PubMed ID: 12077918
    [Abstract] [Full Text] [Related]

  • 30. [Positron emission tomography in the diagnosis and monitoring of patients with nonseminomatous germ cell tumours].
    Büchler T, Simonová K, Fencl P, Abrahámová J.
    Klin Onkol; 2011 May 26; 24(6):413-7. PubMed ID: 22257229
    [Abstract] [Full Text] [Related]

  • 31. Serendipitous detection of testicular seminoma on F-18 FDG positron tomography.
    Ali I, Johns W, Bottger B, Gupta SM.
    Clin Nucl Med; 2007 Mar 26; 32(3):201-2. PubMed ID: 17314595
    [No Abstract] [Full Text] [Related]

  • 32. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group.
    Huddart RA, O'Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK, Vasey P, Harland SJ, Logue J, Daugaard G, Hain SF, Kirk SJ, MacKewn JE, Stenning SP, NCRI Testis Tumour Clinical Study Group.
    J Clin Oncol; 2007 Jul 20; 25(21):3090-5. PubMed ID: 17634488
    [Abstract] [Full Text] [Related]

  • 33. [Positron emission tomography in germ cell tumors in men : Possibilities and limitations].
    Schriefer P, Hartmann M, Oechsle K, Meyer CP, Klutmann S, Fisch M, Bokemeyer C, Oing C.
    Urologe A; 2019 Apr 20; 58(4):418-423. PubMed ID: 30374517
    [Abstract] [Full Text] [Related]

  • 34. The role of positron emission tomography in germ cell cancer.
    De Santis M, Pont J.
    World J Urol; 2004 Apr 20; 22(1):41-6. PubMed ID: 15024601
    [Abstract] [Full Text] [Related]

  • 35. Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Risk-adapted Approach.
    Murthy V, Karmakar S, Carlton J, Joshi A, Krishnatry R, Prabhash K, Noronha V, Bakshi G, Prakash G, Pal M, Menon S, Agrawal A, Rangarajan V.
    Clin Oncol (R Coll Radiol); 2021 Jul 20; 33(7):e315-e321. PubMed ID: 33608206
    [Abstract] [Full Text] [Related]

  • 36. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors.
    Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC.
    Urology; 1999 Apr 20; 53(4):808-11. PubMed ID: 10197862
    [Abstract] [Full Text] [Related]

  • 37. Diffuse splenic metastases from seminoma visualized on FDG PET.
    Lenzo NP, Moschilla G, Patrikeos A.
    AJR Am J Roentgenol; 2004 Aug 20; 183(2):525-7. PubMed ID: 15269051
    [No Abstract] [Full Text] [Related]

  • 38. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.
    Ann Surg; 2009 Dec 20; 250(6):957-63. PubMed ID: 19687736
    [Abstract] [Full Text] [Related]

  • 39. Clinical outcomes of patients with nonseminomatous germ cell tumours and negative postchemotherapy positron emission tomography.
    Buchler T, Simonova K, Fencl P, Jarkovsky J, Abrahamova J.
    Cancer Invest; 2012 Jul 20; 30(6):487-92. PubMed ID: 22506657
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.